Date: 2014-03-16
Type of information: Publication of results in a medical journal
phase:
Announcement: publication of results in Nature Biotechnology
Company: Kymab (UK)
Product: Kymouse™ technology
Action mechanism:
Disease:
Therapeutic area: Technology - Services
Country:
Trial details:
Latest
news: * On March 16, 2014, Kymab, a monoclonal antibody biopharmaceutical company founded on research from the Wellcome Trust Sanger Institute, announced the publication in Nature Biotechnology of a paper describing its breakthrough therapeutic antibody discovery technology, Kymouse™. (Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery - http://dx.doi.org/10.1038/nbt.2825). Scientists at Kymab have engineered a mouse with the full set of genes encoding the human antibody repertoire, calling this new technology Kymouse™. They have demonstrated that these mice develop an enormous range of human antibodies which can be developed as potent drugs to treat a variety of human diseases such as cancer, autoimmune and infectious diseases.
